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SUMMARY: Clinical efﬁcacy and Safety of Mimosa tenuiﬂora Bark Extract in the Rhagades of the Nipple.
M. MUCCI, M. SCIOCCHETTI, C. BENVENUTI
Rhagades of the nipple are an inﬂammatory disease that, during puerperium, could condition breast-feeding. No speciﬁc drug treatments 
are available so far. A topical preparation mainly based on the extracts of Mimosa tenuiﬂora bark, having healing and skin regenerating 
activity, and of Calendula ofﬁcinalis for its synergistic action. A clinical study was carried out to evaluate the efﬁcacy and safety of this cream 
formulation in the treatment of breast rhagades in 65 lactating women, mean age 30.6 years, with rhagades of the nipple. The cream was ap-
plied at each suckling, 6.3 times a day on average, for 4 weeks. Bleeding rhagades healed in 95.6% of cases within 48-72 hours. Fissures and 
erythema relieved until their total disappearance and nipple elasticity improved in 81.5% of cases. There was no need to withdraw lactation, 
except for 3 cases that did not show beneﬁts. Physician’s and mothers’ ﬁnal judgement on drug efﬁcacy was very good in more than 95% of cases 
and all the babies manifested their good acceptance. No adverse reactions were complained by the mothers and babies.
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Introduction
Rhagades of the nipple are the expression of an 
inflammatory disease occurring during puerperium 
that could condition breast-feeding. Etiopathogen-
esis of rhagades of the nipple is still not well defined, 
but anyway the risk to evolve to an infection is high. 
Moreover, the resolution of rhagades is a priority in 
order to avoid the possibility that the mother discon-
tinues breast-feeding due to this very painful distur-
bance. For these reasons, the first objective of rhaga-
des treatment is to heal rapidly the lesion, to block 
the access of germs and to reduce pain, minimising 
the risks of complications and breast-feeding discon-
tinuation. 
No specific drug therapy is available so far: the 
present symptomatic and often empirical treatments 
adopted are mainly aimed to relieve pain. Biblio-
graphic references are scarce and backdated: estrogens 
(1), steroids (2-4), antimycotics (5), antibiotics (4), 
chlorophyll (6) never entered the daily practice.
Important issues in the choice of the treatment 
are the concern of the mother to use any products 
that could interfere with the safety of the child, 
and the risk to overtreat inappropriately a non-in-
fected lesion. 
It is not less important that breast-feeding be con-
tinuous and long-lasting, even beyond the 2nd year: 
the lack of compliance could condition the produc-
tion of milk, and hence, the same maintenance of 
maternal breast-feeding (7).
According to these premises, the use of active 
natural products should be preferred for their po-
tential safety.
A topical preparation based on extracts of Mimosa 
tenuiflora bark, having healing and skin regenerating 
activity, and of Calendula officinalis for its synergis-
tic action was developed. The bark extract of Mimosa 
tenuiflora is a remedy employed in the traditional 
medicine coming from Maya civilisation to cure 
wounds, burns and ulcers. 
The catastrophic events which occurred in Mexico 
during the 1980 decade, (the eruption of the volcano 
Chichonal in Chiapas in 1982, the dramatic natural 
gas explosion in San Juan Ixhuatepec in 1984, the 
earthquake in 1985, the airliner crash in Toluca in 
1986) responsible for a remarkable number of skin 
wounds and burns and the resulting high request 
for appropriate therapies, prompted to find sources 
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for the relevant treatment (8). This requirement led 
to use officially an agent adopted at that time by 
popular medicine: namely the bark of tepescohuite, 
taxonomically corresponding to Mimosa tenuiflora 
(Willdenow) Poiret, which now has become known 
as  “tree of the skin” for its action of facilitating skin 
regeneration and scar prevention (9-12). The peo-
ple of Chiapas (Mexico) obtained from the Mimosa 
tenuiflora bark a brown powder that was directly 
sprinkled on the injured skin to form a firm crust: 
under this layer the damaged skin is protected from 
infections and the clean and fast process of wound 
healing was stimulated (13).
The bark contains saponins, lipids, phytosterols, 
methoxychalcones, kukulkanins, and mainly tannins, 
which exert an antibacterial, antimycotic, astringent 
action as well as an action against free radicals (8, 12-
16). 
The extract of Calendula officinalis has a synergic 
action with M. tenuiflora extract thanks to its content 
in triterpendiol esters, which possess anti-inflamma-
tory, anti-edematous, antibacterial, antioxidant ac-
tivities, and, very relevant to the present indication, 
stimulate the regeneration of new epithelium in skin 
lesions (17-20, 21). The formulation is completed 
by the presence of vitamin A that plays a role in cell 
regulation and differentiation, particularly at the epi-
thelial level. An adequate concentration of vitamin 
Fig. 2 - Physicians’, mothers’ and babies’ final judgement on efficacy and acceptability of the Anti-rhagades Cream.
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Fig. 1 - Fissures, Erythema, Nipple elasticity during the treatment with Anti-rhagades Cream (mean ± SEM).
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A controls the functional and structural integrity of 
epithelial cells, as it stimulates the epithelial basal 
cells to produce mucus whose suppression causes irri-
tations and infections. On the other hand, vitamin E 
is characterised by a marked antioxidant effect. Both 
vitamins can reduce the damage caused by free radi-
cals and play an important role in maintaining the 
physiologic trophism of the skin (22).
Besides the empirical and anecdotic reports of ac-
tivity of the individual components, no clinical data 
are available so far on this combination in this specific 
pathology. The purpose of the study was to evaluate 
the efficacy and safety of this new topical formulation 
based on the bark extract of Mimosa tenuiflora in the 
treatment of rhagades of the nipple occurring during 
breast-feeding. 
Patients and methods
The selection criteria for this open-label study 
considered breast-feeding women in which rhagades 
of the nipple occurred. Patient’s history and clinical 
conditions were registered at baseline, then the wom-
en were treated with the cream applied after each 
suckling for 4 weeks, without the need of washing 
the skin after the application. The topical prepara-
tion contained the bark extract of Mimosa tenuiflora, 
the extract of Calendula officinalis, vitamin A and E 
(Saugella Crema Antiragadi Seno). No other cream 
was used during the study. Once a day, the nipple was 
washed with an appropriate detergent.
The clinical evaluation was carried out at baseline, 
and after 2 and 4 weeks of treatment. Fissure and 
erythema were scored with the following scale 0 = 
absent, 1 = mild, 2 = moderate, 3 = severe, 4 = very 
severe, while nipple elasticity was evaluated accord-
ing to the score 0 = null, 1 = poor, 2 = moderate, 3 
= good, 4 = very good. A final overall judgement was 
expressed by the physician (efficacy), by the mother 
(tolerability) and the baby (acceptability) at the end 
of the treatment with the score 0 = null, 1 = poor, 2 = 
moderate, 3 = good, 4 = very good.
The case report form contained a specific section 
to record the adverse reactions of the mother or of 
the baby.
Results
Sixty-five lactating mothers, mean age 30.6 years 
± 4.8 (SD, range 20-43), presented with rhagades of 
the nipple. The characteristics of the population stud-
ied were: Caucasian race 95.2%, primiparous women 
46.2%, term delivery 92.2%, vaginal delivery 53.1%. 
Breast-feeding started at the 2nd day in 40.7% of cases, 
and at the 3rd day in 42.4% of cases.
The cream was applied after each suckling, 6.3 
times a day on average, 6 times a day for the 53.6% of 
the mothers and 7 times for the 35.7% of mothers.
Bleeding rhagades healed in 95.6% of cases within 
48-72 hours. Fissures and erythema relieved up to 
their total disappearance in 89.2% and in 93.8% of 
cases, respectively, and nipple elasticity improved in 
81.5% of cases (Fig. 1). There was no need to dis-
continue breast-feeding, save 3 cases that did not 
improve. 
Physician’s and mothers’ final judgement of the ef-
ficacy was very good in more than 95% of cases and 
all the babies declared their good acceptance (Fig. 2). 
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Fig. 3 - Antimicrobial effect of Mimosa tenuiflora bark extract with the agar diffusion method (5 mg/0.1 mL of aqueous extract).
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The investigators rated as poor only 2 cases, in agree-
ment with the mothers’ evaluations. No adverse reac-
tions were complained by the mothers and babies.
Discussion
The clinical data of the present study showed the 
remarkable efficacy of the topical treatment based on 
the use of the bark extract of M. tenuiflora in healing 
rhagades of the nipple in lactating women. Tolerabil-
ity of the formulation was excellent, which confirms 
the experimental data on safety. In fact, as toxicity 
is concerned, M. tenuiflora bark extract was judged 
to be non-irritant in the animals after single and re-
peated applications on the skin (23-24). Moreover, it 
is devoid of mutagenic action (25).
The potential of M. tenuiflora bark extract of in-
ducing a delayed contact hypersensitivity was evalu-
ated in skin sensitisation tests in Guinea-pigs: neither 
clinical signs nor cutaneous reactions were detected 
versus controls, though the same animals were just 
used in a previous study showing a sensitisation re-
sponse to a positive sensitiser (40).
In conclusion, this anti-rhagades cream favours 
the formation of a new cutaneous structure, due to 
the antibacterial and antimycotic activity which al-
lows to concomitantly counteract both Candida al-
bicans, often put in relationship with the onset of 
rhagades, and overlapping bacterial infections. The 
microbiological activity profile of Mimosa tenuiflora 
bark extract showed its antibacterial and antimycotic 
properties with a clear growth inhibition of gram 
positive (Staphylococcus aureus), gram negative (Esch-
erichia coli and Pseudomonas aeruginosa) and fungi 
(Candida albicans). Its inhibiting action is lower than 
streptomycin on gram negative and than nystatin on 
Candida, but anyhow it covers a wider range versus 
the antibiotic and the antimycotic drugs taken alone 
(13) (Fig. 3). The healing and protective effect of 
the skin against breast rhagades is the result of the 
pharmacological properties of all the components of 
the end formulation and it is also possible due to the 
compatibility of M. tenuiflora bark with animal tis-
sues. This characteristic was shown by transplanting 
a callous graft of M. tenuiflora into the subcutane-
ous tissue of rats: the vegetable cells survived in the 
animal environment, suggesting the possibility of an 
inter-regni transplantation (27).
M. tenuiflora extract was found to be active on 
cell reproduction when applied topically to Guin-
ea-pig teat in-vivo, with the colchicine test, a sub-
stance which inhibits mitoses (28). In fact, an in-
crease in the mitotic index of mammary cells was 
observed after application of M. tenuiflora extract 
for two weeks versus controls. The astringent effect 
and the increased capillary resistance enhances the 
skin impermeability, which is further protected by 
the antioxidant action of vitamins A and E. The 
fast healing and pain relieving actions of the anti-
rhagades cream reduce the risks of discontinuation 
of maternal lactation. Its preventive use should be 
clinically tested in late pregnancy in women pre-
disposed to rhagades.
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